LOS ANGELES (MarketWatch) -- Japanese stocks sprang higher early Monday, following gains for Wall Street where investors appeared to embrace more upbeat portions of the U.S. January jobs report. The Nikkei Stock Average (JP:NIK) rose 1.3% to 14,649.04, and the broader Topix gained 1.1%, helped by an advance in the U.S. dollar against the Japanese yen compared to the pair's level late Friday. Moving higher early in the session, shares of Isuzu Motors Ltd. (JP:7202) (ISUZF) scaled up by 4.3% after the auto maker reported a 38% rise in third-quarter profit to 89.48 billion yen($874.58 million). Nissan Motor Co.'s (JP:7201) (NSANY) quarterly results are due later Monday, and its shares were up 1.1% ahead of the report.
Top Japanese Companies To Invest In 2015: Insulet Corporation(PODD)
Insulet Corporation, a medical device company, engages in the development, manufacture, and marketing of insulin infusion systems for people with insulin-dependent diabetes in the United States. The company offers OmniPod Insulin Management System (OmniPod System), which consists of the OmniPod disposable insulin infusion device and the handheld wireless personal diabetes manager to provide diabetes management solution for people with insulin-dependent diabetes. It is also involved in the distribution of durable medical equipment, including blood glucose testing supplies, insulin pumps, pump supplies, pharmaceuticals, and other products for the management and treatment of diabetes. The company sells its OmniPod System directly to patients through referrals from healthcare professionals and through patient leads, as well as through third-party distributors; and delivers durable medical equipment to endocrinologists, insurers, and clients. Insulet Corporation was founded in 2000 and is headquartered in Bedford, Massachusetts.
Advisors' Opinion:- [By Rich Smith]
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature a pair of downgrades for document storage company Iron Mountain (NYSE: IRM ) and insulin treatments-equipment maker Insulet (NASDAQ: PODD ) . But the headlines aren't all bad, so before we break the bad news to you, let's start off on a bright note about...
- [By James Brumley]
And just for the record, theme-based buyout speculation doesn’t improve your chances of picking an acquisition target. Back in 2012 after Bristol-Myers Squibb (BMY) bought Amylin for control of its diabetes pipeline following the purchase of Neighborhood Diabetes by Insulet (PODD), pundits were sure it would spark a wave of other diabetes-driven acquisitions. Those other M&A candidates began getting bid up, but as it turns out, no more meaningful buyouts materialized in the diabetes space.
Top Japanese Companies To Invest In 2015: United Fire & Casualty Company(UFCS)
United Fire Group, Inc. engages in the writing of property, casualty, and life insurances. It sells annuities through a network of independent agencies. The company?s property and casualty insurance segment comprises commercial lines insurance products, including surety bonds, personal lines insurance, and assumed insurance. Its life insurance segment consists of deferred and immediate annuities, universal life insurance products, and traditional life insurance products. The company was founded in 1946 and is headquartered in Cedar Rapids, Iowa.
Advisors' Opinion:- [By Jake L'Ecuyer]
Meanwhile, top decliners in the sector included United Fire Group (NASDAQ: UFCS), down 4.9 percent, and Hilltop Holdings (NYSE: HTH), off 3.7 percent.
5 Best Trucking Stocks To Watch Right Now: Abbott Laboratories(ABT)
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. The company offers adult and pediatric pharmaceuticals for rheumatoid and psoriatic arthritis, ankylosing spondylitis, psoriasis, and Crohn's disease; dyslipidemia; HIV infection; prostate cancer, endometriosis and central precocious puberty, and anemia caused by uterine fibroids; respiratory syncytial virus; adult males who have low or no testosterone; secondary hyperparathyroidism; hypothyroidism; and pancreatic exocrine insufficiency, as well as anesthesia products. It also provides diagnostic products, such as immunoassay systems; chemistry systems; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological, and infectious diseases; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infections agents; genomic-b ased tests; hematology systems and reagents; and point-of-care diagnostic systems and tests for blood analysis. In addition, the company offers a line of pediatric and adult nutritional products. Further, it provides coronary, endovascular, vessel closure, and structural heart devices, such as drug-eluting stent systems, coronary metallic stents, balloon dilatation products, coronary guidewires, vessel closure devices, carotid stent systems, percutaneous valve repair systems, and drug eluting bioresorbable vascular products. Additionally, the company provides blood glucose monitoring meters, test strips, data management software, and accessories for people with diabetes; and medical devices for the eye, including cataract surgery, lasik surgery, contact lens, and dry eye products, as well as branded generic pharmaceutical products. Abbott primarily serves retailers, wholesalers, hospitals, and health care facilities. Abbott was founded in 1888 and is headquartered in Abbott Park, Illinois.
Advisors' Opinion:- [By Maxx Chatsko]
After spinning off its pharmaceutical business -- and most of its dividend, essentially -- you may think Abbott Laboratories (NYSE: ABT ) is relegated to a boring medical-device company. Heart stents just aren't as sexy as the megablockbuster drugs now being wielded by AbbVie� (NYSE: ABBV ) . The spinoff also took a promising�pipeline and most of the former company's dividend, which may make investors think twice about owning a slow-growing, mediocre-paying company such as Abbott.�
- [By Monica Gerson]
Analysts expect Abbott Laboratories (NYSE: ABT) to report its Q3 earnings at $0.51 per share on revenue of $5.40 billion. Abbott shares gained 0.86% to $34.00 in after-hours trading.
Top Japanese Companies To Invest In 2015: Oaktree Capital Group LLC (OAK)
Oaktree Capital Group, LLC (Oaktree) is a global investment management firm focused on alternative markets. Oaktree manages funds in investment strategies that fall into the six asset classes, which include distressed debt, corporate debt, control investing, convertible securities, real estate and listed equities. As of June 30, 2011, the Company�� assets under management (AUM) totaled $79.5 billion. The Company�� manager is Oaktree Capital Group Holdings GP, LLC. The Company manages assets on behalf of other institutional investors in the world, including 70 of the 100 United States pension plans, 37 states in the United States, over 350 corporations, over 300 university and charitable endowments and foundations, and over 150 non-United States institutional investors, including six of the top 10 sovereign wealth fund nations.
Funds managed by Oaktree include both separate accounts and commingled funds. The commingled funds include open-end and closed-end limited partnerships for which the Company or a subsidiary serves as the general partner or, in certain limited cases, co-general partner. Oaktree makes principal investments in these funds.
Advisors' Opinion:- [By Amanda Alix]
The investment-to-REIT model is alive and well
Before the very end of last year, those involved in the single-family purchase and rental business were largely private equity groups�like the Blackstone Group (NYSE: BX ) , Colony Financial (NYSE: CLNY ) , and Oaktree Capital (NYSE: OAK ) , which bought up distressed properties by the truckload.
Top Japanese Companies To Invest In 2015: Alexion Pharmaceuticals Inc.(ALXN)
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products for treating patients with severe and life-threatening disease states in the United States, Europe, Latin America, Japan, and the Asia Pacific. It focuses on developing products for the treatment of diseases in the areas of hematology, nephrology, neurology, ophthalmology, and cancer. The company develops and commercializes Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder. It also conducts various Phase II clinical trail programs on Soliris for its usage for the treatment of cold agglutinin disease; atypical hemolytic uremic syndrome; presensitized renal transplant; kidney transplant for catastrophic antiphospholipid syndrome; ABO incompatible renal transplant; dense deposit disease; myasthenia gravis; neuromyelitis optica; and dry a ge-related macular degeneration. In addition, the company conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry; and Phase I clinical trails on Samalizumab for the treatment of oncology diseases, such as chronic lymphocytic leukemia and multiple myeloma. Alexion Pharmaceuticals, Inc. serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company was founded in 1992 and is headquartered in Cheshire, Connecticut.
Advisors' Opinion:- [By MONEYMORNING.COM]
There is no crystal ball that's 100% accurate when experimental drugs are concerned, but here are some telling questions that can narrow your search.
Questions to Answer Before You Buy In Does the drug fulfill an unmet need?
Alexion Pharmaceuticals Inc.'s (Nasdaq: ALXN) Soliris (eculizumab) is the only drug approved to treat paroxysmal nocturnal hemoglobinuria (PNH), an extremely rare, lethal blood disorder. It is also the only therapy approved to treat atypical hemolytic uremic syndrome (aHUS), a genetic condition that can result in sudden and progressive damage to vital organs, leading to stroke, heart attack, and kidney failure. Five years ago, ALXN shares were selling for about $18.50. They recently hit a high of $180.51 - thanks to Soliris, and Soliris alone. Is it a "breakthrough" drug?
A "Breakthrough Therapy" (BT) is actually a designation awarded by the FDA for a drug that "...is intended alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition and [has] preliminary clinical evidence [that] indicates the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development." In 2012, the FDA granted Roche/Genetech's Gasyva a BT designation and then approved it for marketing in 2013. It treats chronic lymphocytic leukemia (CLL) and is expected to be a big blockbuster - as are the other three breakthrough therapies that were approved last year. Can its market produce blockbuster income?
This can mean a huge market, such as patients with high cholesterol - think Pfizer Inc.'s (NYSE: PFE) Lipitor (atorvastatin calcium), the bestselling drug of all time - or a small market that will pay for highly priced orphan drugs for rare diseases. BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a company that specializes in the - [By Ben Levisohn]
Still, investors shouldn’t buy the sector willy-nilly. Porges recommends Celgene (CELG) and Gilead (GILD), among large caps, and notes that less-pricey stocks like Amgen (AMGN) should hold up better, as should midcaps with earnings and products, such as Alexion (ALXN).
No comments:
Post a Comment